Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC, commonly known as Hikma, is a leading global pharmaceutical company headquartered in the United Kingdom. Founded in 1978, Hikma has established a strong presence in key operational regions, including the Middle East, North Africa, and the United States. The company operates primarily in the generic and branded pharmaceuticals sectors, focusing on injectable medications, oral solids, and complex generics. Hikma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic areas, including oncology, pain management, and infectious diseases. With a robust market position, Hikma has achieved significant milestones, including numerous FDA approvals and a growing pipeline of new therapies. The company's dedication to improving patient outcomes and expanding access to essential medicines underscores its reputation as a trusted leader in the pharmaceutical industry.
DitchCarbon Score
How does Hikma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hikma Pharmaceuticals's score of 35 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hikma Pharmaceuticals's reported carbon emissions
In 2023, Hikma Pharmaceuticals reported total carbon emissions of approximately 123,638,000 kg CO2e, comprising 43,830,000 kg CO2e from Scope 1 and 79,897,000 kg CO2e from Scope 2 emissions. Additionally, the company recorded significant Scope 3 emissions of about 925,152,000 kg CO2e, which includes emissions from capital goods, purchased goods and services, and employee commuting. Hikma has demonstrated a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. The company continues to monitor and report its emissions, reflecting an awareness of its environmental impact. The emissions per unit of revenue for 2023 were approximately 0.043 kg CO2e per USD, indicating a focus on improving efficiency alongside revenue growth. Overall, while Hikma Pharmaceuticals has made strides in transparency regarding its emissions, further details on specific reduction strategies or targets would enhance its climate commitment narrative.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2013 | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 20,831,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 51,424,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hikma Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
